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Background: The thyroid hormone, 3, 3′, 5-triiodo-L-thyronine (T3), has been shown to modulate cellular processes
via interactions with thyroid hormone receptors (TRs), but the secretory proteins that are regulated to exert these
effects remain to be characterized. Brain-specific serine protease 4 (BSSP4), a member of the human serine protease
family, participates in extracellular matrix remodeling. However, the physiological role and underlying mechanism of
T3-mediated regulation of BSSP4 in hepatocellular carcinogenesis are yet to be established.
Methods: The thyroid hormone response element was identified by reporter and chromatin immunoprecipitation
assays. The cell motility was analyzed via transwell and SCID mice. The BSSP4 expression in clinical specimens was
examined by Western blot and quantitative reverse transcription polymerase chain reaction.
Results: Upregulation of BSSP4 at mRNA and protein levels after T3 stimulation is a time- and dose-dependent
manner in hepatoma cell lines. Additionally, the regulatory region of the BSSP4 promoter stimulated by T3 was
identified at positions −609/-594. BSSP4 overexpression enhanced tumor cell migration and invasion, both in vitro
and in vivo. Subsequently, BSSP4-induced migration occurs through the ERK 1/2-C/EBPβ-VEGF cascade, similar to
that observed in HepG2-TRα1 and J7-TRα1 cells. BSSP4 was overexpressed in clinical hepatocellular carcinoma (HCC)
patients, compared with normal subjects, and positively associated with TRα1 and VEGF to a significant extent.
Importantly, a mild association between BSSP4 expression and distant metastasis was observed.
Conclusions: Our findings collectively support a potential role of T3 in cancer cell progression through regulation
of the BSSP4 protease via the ERK 1/2-C/EBPβ-VEGF cascade. BSSP4 may thus be effectively utilized as a novel
marker and anti-cancer therapeutic target in HCC.
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The thyroid hormone (TH) acts as a pleiotropic regulator
in growth, differentiation, proliferation and other physio-
logical processes by interacting with thyroid hormone re-
sponse elements (TREs) located in the regulatory regions
of target genes [1]. Indeed, TH is required to maintain the
metabolic rate and oxygen consumption in almost all
tissues [2]. TRs interact with the retinoid X receptor (RXR)* Correspondence: khlin@mail.cgu.edu.tw
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unless otherwise stated.to form heterodimers that influence target genes by binding
to their TRE regions [3]. Two TR genes, TRα and TRβ,
have been identified on human chromosomes 17 and 3,
respectively. Alternative splicing and promoter usage of
primary transcripts have been shown to generate TRα1,
TRα2, TRβ1 and TRβ2 receptor isoforms [4].
Previous microarray experiments by our group demon-
strated that numerous genes encoding coagulation factor
system components, plasma proteins, nuclear receptor co-
activator, anti-metastatic proteins, proteases and oncogenes
are regulated by T3 [2]. Recently, we employed stable
isotope labeling with amino acids in cell culture (SILAC)-
based quantitative proteomic approaches, with a view totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[5]. Consequently, several secreted proteins and the
urokinase plasminogen activator (uPA) system were
identified and quantified, clearly indicative of a role of T3
in the modulation of secretory proteins. Earlier proteomic
analyses further revealed a significant increase in brain-
specific serine protease 4 (BSSP4) involved in the uPA sys-
tem [6], quantified in one of the three SILAC experiments
(T3/Td >3), in T3-treated HepG2-TRα1 cells.
BSSP4 is a member of the human chromosome 16p13.3
serine protease family. The protease is also known as
tryptase ε and protease serine S1 family member 22 [7].
Previous study by Yasuda et al. [6] reported that BSSP4
catalyzes the progression of zymogen pro-uPA to active
uPA. The uPA system, a serine protease family comprising
tissue-type plasminogen activator (tPA), uPA, uPA recep-
tor (uPAR) and plasminogen activator inhibitors (PAIs), is
universally found in almost all cancer types [8]. While
BSSP4 has been shown to play a role in different cancers
[9], few studies to date have focused on its specific func-
tions in cancer biology.
In the current study, we investigated T3-mediated
regulation of BSSP4 and its underlying physiological sig-
nificance in hepatoma cell lines. Our results indicate that
T3-regulated BSSP4 induces cancer progression via the
ERK1/2-C/EBPβ-VEGF cascade in hepatoma cells. More-
over, BSSP4 is consistently overexpressed in HCC patients,
compared with normal subjects, supporting its utility as a
novel marker.
Results
Effects of T3 on BSSP4 mRNA and protein expression
Several isogenic HepG2 cell lines stably expressing high
levels of wild-type TRα1 and TRβ1 (HepG2-TRα1 and
HepG2-TRβ1, respectively) were established. Specifically,
four HepG2 cell lines, HepG2-TRα1#1, HepG2-TRα1#2,
HepG2-TRβ1#1 and HepG2-Neo, and J7-TRα1, and par-
ental cells expressing various levels of TR (Figure 1A)
were used for analyses. Notably, BSSP4 expression was
stimulated by T3 in the HepG2-TRα1#1, HepG2-TRα1#2
and HepG2-TRβ1 cell lines at both the mRNA (Figure 1B)
and protein levels (Figure 1C) in a time- and dose-
dependent manner. In contrast, T3 had a marginal or
no effect on BSSP4 expression in HepG2-Neo cells
(Figure 1B, C). Moreover, we have examined the BSSP4
regulation by T3 in parental cells expressing endogenous
TR, such as J7 (Figure 1D, I), Huh7 (Figure 1D, II) and
SK-Hep-1 cells (Additional file 1: Figure S1B). We have
depleted the TRα and TRβ expression with siRNA in SK-
Hep1 cell (Additional file 1: Figure S1A). The BSSP4 regu-
lation was abolished significantly after silencing the TRα
and TRβ expression (Additional file 1: Figure S1B). Several
HCC cell lines expressing low levels of endogenous TR
proteins can be induced the BSSP4 expression with alesser extent after T3 application. According to the data,
we conclude the BSSP4 regulation by T3 can be observed
in the parental cells as well as TR overexpression system.
T3 induces BSSP4 expression at the transcriptional level
The reporter assay was performed to determine the pos-
ition of the thyroid hormone response element (TRE) to
further clarify the regulatory effects of T3 on BSSP4 at
the transcriptional level. The BSSP4 5′-flanking region
encompassing nucleotides −2066/-7 (relative to the tran-
scription initiation site) with numerous predicted puta-
tive TREs (Figure 1E) was cloned and inserted upstream
of the luciferase reporter gene in pGL2-luc (Construct
p1) to generate Construct p2. The pA3TK-luc construct
containing a minimum thymidine kinase promoter was
designated Construct p6. Serial deletion mutants were
additionally generated (Figure 1E). The transcriptional
activities of the BSSP4 promoter fragments are illustrated
in Figure 1E. Among these, only the p10 construct con-
taining two putative TREs was activated about 3.5-fold by
T3 in HepG2-TRα1 cells. The two TREs in the p10 frag-
ment were sequentially mutated to yield p12 and p13 con-
structs. However, upon mutation of the other putative TRE
(pal), luciferase activity of the p12 construct was com-
pletely abolished (Figure 1E). These findings suggest that
T3 regulates BSSP4 at the transcriptional level by binding
to the putative TRE site between positions −628/-498 (p10)
encompassing a pal-like sequence between positions −609
to −594 (AGGTCCTTGCTGTCCT).
TR and RXR proteins form a complex with TRE (−609 ~−594)
within the BSSP4 promoter
To further determine whether BSSP4 TRE (pal) is directly
targeted by TR proteins, the ChIP assay was performed.
TR proteins were clearly associated with the TRE region
of the BSSP4 promoter in vivo both HepG2-TRα1 and J7-
TRα1 cells (Figure 1F). Notably, TRα1 and RXRα were re-
cruited to the TRE-binding site (Figure 1F, lanes 3, 4),
whereas control IgG produced only background levels
(Figure 1F, lane 2). Accordingly, we propose that the TRα1
and RXRα complexes bind to the BSSP4 promoter for
transcriptional regulation.
BSSP4 is associated with cancer progression in vitro
We detected the BSSP4, TRα and TRβ expression in six
hepatoma cell lines (Additional file 2: Figure S2). The
positive correlation of BSSP4 vs. TRα/TRβ expression was
observed in most of the hepatoma cell lines. To determine
the specific functions of BSSP4, control cell lines (Figure 2A,
Huh7-control #1 and #2) and those overexpressing BSSP4
(Figure 2A, Huh7-BSSP4 #1 and #2) were established.
BSSP4 has been detected in several cancer types [9]. The
protein was originally identified as a member of the human
serine protease family, also designated tryptase ε [7]. In
Figure 1 (See legend on next page.)
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Figure 1 T3-regulates BSSP4 mRNA and protein expression in HepG2 cells. (A) Expression of TR in cell extracts of overexpressed-TR and
parental cell lines was determined via Western blotting. The positions of 47 kDa TRα1 and 55 kDa TRβ1 are indicated. BSSP4 expression was
determined in the three stable HepG2-TR lines and HepG2-neo cells at 12–48 h in the absence or presence of 1 and 10 nM T3 using (B) Q-PCR
and (C) Western blotting. (D) T3 stimulated BSSP4 expression in J7 and Huh7 cells expressing endogenous TR was determined by Western
blotting. (E) HepG2-TRα1 cells were transfected with the luciferase reporter plasmid driven by the BSSP4 5′-flanking region (positions −2066 to −7
containing twelve putative TRE sites) with or without pA3TK-luc. Promoter activities were calculated, relative to 0 nM T3 (+T3/-T3), and further
normalized to the pA3TK-luc control as well as β-galactosidase activity (T3-induced changes were normalized to that of β-gal). Columns, mean
values obtained from at least three independent experiments performed in triplicate; bars, SE. (F) ChIP assay demonstrating that TR is recruited to
the BSSP4 5′-flanking region, together with RXR in HepG2-TRα1 and J7-TRα1 cells. Two sets of primers for BSSP4 TRE, positive control TRE (FURIN)
and negative control (GAPDH) were prepared.
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in extracellular matrix remodeling during cancer cell
progression and development [10], we aimed to ascertain
whether BSSP4 also plays a role in cancer processes.
The proliferation rates of the two stably overexpressing
BSSP4 cell lines (Huh7-BSSP4 #1 and #2) were similar
to those of the two control cell lines (Huh7-control #1
and #2), as shown in Additional file 3: Figure S3A.Figure 2 BSSP4 promotes cell motility in vitro. Expression of BSSP4 was
(control #1, #2) with Western blotting (A). (B) Migration and (C) invasion ab
lines using a Transwell assay. The number of cells traversing the filter to th
an index of migration and invasion activity. Transwell filters were stained w
quantified in the right panel. (D) Expression of BSSP4 in Mahlavu-control ce
Western blotting. The migration ability was also examined with a TranswelHowever, cell lines overexpressing BSSP4 displayed sig-
nificantly increased (~3 to 6-fold) migration (Figure 2B)
and invasion (Figure 2C), compared with control cells. Our
results indicate that BSSP4 functions in cell migration and
invasion, but has no effect on cell growth. Furthermore,
after depleted BSSP4 in Mahlavu cells, the migration ability
of Mahlavu-BSSP4-depleted cells was decreased com-
pared with Mahlavu–control cells by the Transwell assaydetected in BSSP4-overexpressing clones (#1, #2) and controls
ilities were analyzed in two BSSP4 overexpressing and two control cell
e lower chamber was expressed as the total number of cells to provide
ith crystal violet in the left panel, and migration and invasion abilities
lls (#1, #2) and Mahlavu-BSSP4-KD cells (#1, #2) was determined by
l assay (E).
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depleted and BSSP4-overexpressed cells, BSSP4 has the
ability to accelerate tumor cell migration.
BSSP4 influences EMT progression markers
To further clarify the mechanisms involved in BSSP4-
regulated cell migration and invasion, we selected several
markers of epithelial-mesenchymal transition (EMT) for
examination [11]. Figure 3A presents BSSP4 expression
levels in Huh7-BSSP4 and Huh7-control cells. The N-
cadherin level was increased and E-cadherin decreased in
BSSP4-overexpressing cells (Huh7-BSSP4 #1 and #2),
compared with control cells (Huh7-control #1 and #2), on
a Western blot (Figure 3B). Based on these results, we
propose that the EMT process is involved in BSSP4-
mediated cancer cell progression.
BSSP4 and T3 regulate cancer-related molecules
Previously, Yasuda et al. [6] demonstrated that BSSP4 is a
serine protease that catalyzes the progression of zymogen
pro-uPA to form active uPA. Moreover, the uPA-uPAR
system has been linked to the mitogen-activated protein
kinase (MAPK)/extracellular signal-regulated kinase (ERK)
signaling pathway [12-14]. ERK kinases are frequently
abnormally activated in most human cancers, leading to
proliferation and acceleration of other oncogenic processes,
such as angiogenesis and survival [15]. Accordingly, we
examined whether the ERK pathway is implicated inFigure 3 T3 and BSSP4 enhance the expression of intracellular and ex
(Huh7-BSSP4 #1, #2) and controls (Huh7-control #1, #2) were detected via W
E-cadherin and N-cadherin, in cell extracts (B), phosphate-ERK and C/EBPβ
examined using Western blotting. Expression patterns of phosphate-ERK an
HepG2-TRα1 and J7-TRα1 cells were established.BSSP4-induced phenotypes. Our results showed marked
upregulation of phosphate-ERK in BSSP4-overexpressing
cells (Huh7-BSSP4 #1 and #2), compared with control
cells (Huh7-control #1 and #2) (Figure 3C). A number of
groups have identified CCAAT/enhancer-binding protein
beta (C/EBPβ and vascular endothelial growth factor
(VEGF) as ERK downstream genes [16]. VEGF facilitates
the formation of new vessels in angiogenesis and plays a
critical role in tumor metastasis. Its expression is highly
correlated with tumor cell metastasis potency in various
cancers [17]. Similarly, C/EBP plays diverse roles in mul-
tiple cellular processes, such as the cell cycle, extracellular
signaling, tissue development, and is implicated in cancer
processes [18]. Subsequently, we investigated whether C/
EBPβ and VEGF are targeted by BSSP4. Notably, C/EBPβ
was upregulated in the nucleus and VEGF was extensively
secreted into the medium in BSSP4-expressing cells
(Huh7-BSSP4 #1 and #2), compared with their control
counterparts (Huh7-control #1 and #2) (Figure 3C, D).
We further examined whether this BSSP4-mediated
mechanism occurs in T3-regulated hepatoma cells. Our re-
sults showed upregulation of nuclear phosphate-ERK and
C/EBPβ after T3 stimulation in both HepG2-TRα1 and J7-
TRα1 cells (Figure 3E). Additionally, VEGF secretion into
the medium was increased in T3-treated HepG2-TRα1 and
J7-TRα1 cells (Figure 3F). Accordingly, we conclude that
stimulation of ERK, C/EBPβ and VEGF expression by T3
in HepG2-TRα1 or J7-TRα1 cells is mediated via BSSP4.tracellular cancer-related molecules. BSSP4-overexpressing clones
estern blotting (A). Expression of EMT-related markers, such as
in the nucleus (C), and VEGF in the conditioned medium (D) were
d C/EBPβ (E) in the nucleus and VEGF in the medium (F) in both
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signaling pathway
In view of the above results, we hypothesized that T3
regulates BSSP4 through the ERK-C/EBPβ-VEGF cas-
cade, leading to cancer cell progression. To examine this
possibility, we treated stable Huh7-BSSP4 cell lines with
DMSO and U0126, a MEK inhibitor [19,20], followed
by the migration and invasion assays. The migration
and invasion ability of BSSP4-overexpressing cells
(Huh7-BSSP4 #1 and #2) was increased about 4-fold,
relative to control cells (Huh7-control #1) (Figure 4A, B).
However, this increase was abolished by approximately
25% upon U0126 treatment of BSSP4-expressing cells
(Huh7-BSSP4 #1 and #2) (Figure 4A, B). The quantified
results are shown in Figure 4A, B, lower panel. Based on
these findings, we propose that the ERK pathway is impli-
cated in BSSP4-mediated cell migration. We further ascer-
tained whether this phenomenon occurs in T3-regulated
hepatoma cells. As expected, the migration and invasion
ability of J7-TRα1 cells was enhanced (~3.5-fold) after T3
stimulation (Figure 4C, D), which was attenuated (~30%)
upon U0126 treatment (Figure 4C, D). The quantified re-
sults are illustrated in Figure 4C, D, lower panel. Thus,
BSSP4 appears to mediate cell migration through the ERK
signaling pathway.
The ERK-C/EBPβ-VEGF pathway is involved in BSSP4 and
T3-mediated cell migration
We observed upregulation of p-ERK, C/EBPβ and VEGF
in both BSSP4-overexpressing and T3-treated hepatoma
cells. Moreover, the ERK signaling pathway is clearly in-
volved in BSSP4- and T3-modulated cell migration ability.
This led us to investigate whether C/EBPβ and VEGF are
influenced by blocking the ERK signaling pathway. Our
results showed that expression levels of nuclear p-ERK
and C/EBPβ are decreased in stable Huh7-BSSP4 cells
after U0126 treatment, compared with those in control
cells (Figure 5A, lanes 7, 8 vs 3, 4). VEGF secretion into
the medium of stable Huh7-BSSP4 cells was additionally
attenuated following U0126 treatment (Figure 5B, lanes 7,
8 vs 3, 4). We further determined whether BSSP4 has a
similar influence in T3-treated hepatoma cells. Interest-
ingly, in both T3-treated HepG2-TRα1 and J7-TRα1 cells,
expression of p-ERK and C/EBPβ in the nucleus was
blocked after U0126 treatment, compared with control
cells (Figure 5C, D). Furthermore, VEGF secretion into
the medium was significantly attenuated following U0126
treatment in both T3-treated cell lines (Figure 5E, F).
Furthermore, the p-VEGFR and VEGFR expression were
determined in BSSP4- and TR-overexpressing cells. The
p-VEGFR level was increased in BSSP4-overexpressing
cells. Consistently, the p-VEGFR expression was up-
regulated after T3 treatment in the HepG2-TRα cell
(Additional file 4: Figure S4). A Similar result can beobserved in J7-TRα cell (data not shown). Therefore,
we speculate that BSSP4 influenced tumor motility
may through VEGF-VEGFR cascade.
The relationship between BSSP4 and cancer-related
molecules and pathways was investigated using Human
Cancer PathwayFinder RT Profiler metastasis-associated
PCR Arrays (Quiagen; Kowloon, Hong Kong). We found
20 genes were altered (about 1.5 ~ 3 fold) in BSSP4
overexpressing cells. The BSSP4-regulated molecules
are divided into several categories based on the functions
such as cytokines and chemokine pathway (IL-18, CCL7,
CXCL12), cell to cell adhesion pathway (PNN, SYK,
MCAM), metastasis-related genes (GNRH1, TIMP2,
KISS1R, TSHR, TRPM1, SSTR2), transcription factors
and regulators (RORB, NR4A3, SMAD2, SMAD4),
ECM cleavage pathway (MMP7) and cell cycle regulation
(PTEN) were altered (Additional file 5: Figure S5). Thus,
BSSP4 may play a role in cancer progression via alteration
of related genes. Our results collectively indicate that
BSSP4 is upregulated by T3, and subsequently activates
the ERK-C/EBPβ-VEGF cascade to promote cancer cell
progression.
BSSP4 is associated with cell motility in vitro and in vivo
To verify whether the in vitro effect of BSSP4 also oc-
curs in vivo, SCID mice were injected with Huh7-BSSP4
and Huh7-control cells. However, no tumors were ob-
served in the lung and liver in either cell line. Based on
these findings, we speculated that the Huh7 hepatoma
cell line is non-tumorigenic. Therefore, a stable J7-
BSSP4 cell line was established. Notably, the BSSP4
level was increased in two stably expressing BSSP4
clones (J7-BSSP4 #1 and #2), compared to two control
cell lines (J7-control #1 and #2) (Figure 6A). Similar to
Huh-7 cells, proliferation was not influenced in stable
BSSP4-overexpressing J7 cell lines, compared with con-
trols (Additional file 3: Figure S3B). Moreover, BSSP4-
overexpressing cells (J7-BSSP4 #1 and #2) showed higher
migration and invasion abilities, relative to their control
cell counterparts (J7-control #1 and #2, respectively)
(Figure 6B, C). The in vitro phenotypes were similar
between Huh7-BSSP4 and J7-BSSP4 cell lines (Figures 2
and 6). Additionally, we have established J7-TR-BSSP4
knockdown (KD) cell lines. The BSSP4 expression in
control cells was induced by T3, however, the induction
was abolished in the J7-TR-BSSP4 KD cells (Figure 6D, E).
Obviously, the migration ability of J7-TR-control cells was
enhanced by T3 stimulation, however, the effect was atten-
uated in the J7-TR-BSSP4 KD cells (Figure 6E) restoring a
more “normal” phenotype. The migration ability was sig-
nificantly (p < 0.018) restored in J7-TR-BSSP4-KD-T3 cell
line after T3 treatment compared to the BSSP4 silencing
J7-TR-BSSP4-KD cell line (Figure 6E, right panel).
Based on the evidences, the migration phenotype in
Figure 4 BSSP4- and T3-mediated cell migration occurs via the ERK signaling pathway. The transwell migration (A, C) and invasion assays
(B, D) were performed for two BSSP4-expressing (Huh7-BSSP4 #1, 2) and one control (Huh7-BSSP4 #1) cell line (A, B), and J7-TRα1 cells (C, D).
Stable lines (105) (A, B) and T3-treated J7-TRα1 (5 × 104) (C, D) cells were treated with DMSO and U0126 (10 μM) added to the upper chamber of
Transwell units, followed by incubation for 24 h. Transwell filters were stained with crystal violet in the upper panel, and migration ability quantified in
the lower panel. Values are shown as fold increase of Huh7-BSSP4 relative to Huh7-control, and T3 relative to Td. Differences were analyzed using
One-way ANOVA, *P < 0.05.
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BSSP4-KD condition.
SCID mice were employed to examine whether the
in vitro effects of J7-BSSP4 can be replicated in vivo.
Significantly, in SCID mice, J7-BSSP4 cells formed
higher numbers of lung foci (Figure 7A) and had a
higher metastatic index (Figure 7B), compared with con-
trol cells, as well as elevated BSSP4 expression, as evi-
dent from H & E staining (Figure 7C, D, upper panel)
and IHC (Figure 7C, D, lower panel) analyses, respect-
ively. Based on these findings, we conclude that BSSP4promotes cell migration and invasion in J7 hepatoma
cells, both in vitro and in vivo.
BSSP4 is upregulated in human HCC and animal models
Next, we examined the clinicopathologic significance of
BSSP4 expression in HCC and evaluated the correlation
between TRs and BSSP4. Overall, 74 consecutive HCC
patients were enrolled, and their BSSP4 levels analyzed
using Western blot. Among the 74 HCC sample pairs,
the BSSP4 was overexpressed in 52.7% (39 of 74) cancer-
ous tissues, compared with matched noncancerous tissues.
Figure 5 T3 and BSSP4 promote cell migration via the ERK-C/EBPβ-VEGF cascade. We determined the expression patterns of phosphate-ERK
and C/EBPβ in the nucleus (A, C, D) and VEGF in conditioned medium (B, E, F) in BSSP4-expressing clones (Huh7-BSSP4 #1, #2), controls (Huh7-control
#1, #2) (A, B), and T3-stimulated (0, 1, 10 nM) HepG2-TRα1 (C, E) and J7-TRα1 (D, F) treated with DMSO or U0126 (10 μM) using Western blot analysis.
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by about 29.7% (22 of 74) in cancerous tissues. We have
examined the p-ERK in clinical samples (Figure 8A). The
p-ERK expression was higher in tumor than the normal
counter- parts, and the tendency was the same with
BSSP4 expression. Increased BSSP4 expression and
concomitantly elevated TR levels in HCC tissues of 12
representative paired HCC specimens are presented in
Figure 8A. The correlation between TRs and BSSP4 was
additionally analyzed. Linear regression analysis revealed a
significant positive correlation between BSSP4 expression
and TR levels, based on the T/N ratio (Spearman correl-
ation coefficient = 0.445; 95% confidence interval (CI) =
0.154-0.665; P = 0.003) (Figure 8B). We have examinedthe correlation between BSSP4 and several parameters.
A mild association between BSSP4 expression and distant
metastasis is observed. Patients with T/N < 1.5 are less
likely to have distant metastasis > 1 year than patients with
T/N > 1.5 (P = 0.043). BSSP4 and VEGF levels in HCC tis-
sues were determined using the Q-RT-PCR. We observed
overexpression of BSSP4 and VEGF in 50% (26 of 52) and
61.5% (32 of 52) clinical specimens of HCC, respectively.
Additionally, the T/N ratios of VEGF and BSSP4 expres-
sion revealed a significant positive correlation (Spearman
correlation coefficient = 0.504; 95% confidence interval
(CI) = 0.260-0.687; P = 0.0001) (Figure 8C; Table 1). We
have added statistics information in “Additional file 6:
Figure S6” to show the correlation in BSSP4 expression
Figure 6 BSSP4 increases cell motility in vitro. Expression of BSSP4 was detected in BSSP4-expressing clones (#1, #2) and controls (control #1,
#2) with Western blotting (A). (B) Migration and (C) invasion abilities of two BSSP4-overexpressing and two control cell lines were analyzed using
a Transwell assay. Transwell filters were stained with crystal violet in the upper panel, and migration and invasion abilities quantified in the lower
panel (B, C). The BSSP4 expression in J7-TR-control cells and J7-TR-BSSP4-KD cells treated with/without T3 was detected by Western blotting (D).
The migration ability was determined with a Transwell assay (E, left panel), and the quality index was illustrated in E, right panel. Values are
presented as fold increase of J7-BSSP4, relative to J7-control. Differences were analyzed using One-way ANOVA, *P < 0.05.
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bilirubin level was significantly (P = 0.043), cirrhosis was
marginally (P = 0.057) associated with BSSP4 expression.
Notably, the expression of BSSP4 between TRα (Additional
file 7: Figure S7A, Spearman r = 0.63, P < 0.001) and TRβ
(Additional file 7: Figure S7B, Spearman r = 0.6, P < 0.001)
were demonstrated a significantly positive correlation in
public Oncomine microarray data sets. Further, Kaplan-
Meier analysis was used to analyze the correlation of BSSP4expression with clinical parameters, including tumor size,
tumor grade, tumor number, microvascular invasion and
macrovascular invasion…etc. (Additional file 8: Figure S8).
Based on the data, the overall survival was significantly
associated with HBsAg, ascites and tumor number. The
HBsAg status was significantly associated with distant
metastasis > 1y (p < 0.001). Moreover, the BSSP4 T/N
ratio was also significatnly associated with distant me-
tastasis > 1y (p = 0.043). The significantly associated
Figure 7 BSSP4 increases cell motility in vivo. The images (A) depict tumor foci of lung sections (arrows indicated) in both J7-control (A, I)
and J7-BSSP4 cells (A, II). The metastatic index (fold, density of tumor numbers in per cm2 area) in lung for J7-control and J7-BSSP4 cells is
specified (B). Tumor foci and BSSP4 expression of J7-control (C, left panel) and J7-BSSP4 cells (C, right panel) were examined using H & E staining
(C, upper panel) or IHC (C, lower panel), respectively. The tumor foci covered almost all areas seen in (D) (C and D represent different magnifications,
arrowheads in C are magnified in D). Values are presented as fold increase of J7-BSSP4, relative to J7-control. Differences were analyzed using One-way
ANOVA, *P < 0.05.
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file 8: Figure S8. Finally, the significant (p < 0.01) correl-
ation between TR and BSSP4 was found in clinical HCC
specimens (Figure 8A, B, C). Thus, the TR and BSSP4
expression levels were positively associated in vitro or
in vivo. Both our in vitro and in vivo findings support the
use of BSSP4 as an effective therapeutic target for HCC
therapy.
To determine the function of BSSP4 induced by T3,
J7-TRα1 cells were employed. BSSP4 mRNA and protein
expression was regulated in a dose- and time-dependent
manner in J7-TRα1 cells (Figure 8D). To further investi-
gate whether the T3-regulated effect in vitro is replicable
in vivo, SCID mice were injected with J7-TRα1 cells and
treated under several T3 conditions [5]. Mice injected
with J7-TR cells displayed multiple macroscopic lung
tumor nodules, as determined by hematoxylin and eosin
(H & E) staining. Tumor size was calculated per cm2 of
lung section and the metastatic index was significantly
greater in hyperthyroid mice than in euthyroid condition.Higher T3 levels (hyperthyroid conditions) enhanced BSSP4
expression and number of lung foci, as observed with IHC
(Figure 8E, upper panel) and H & E staining (Figure 8E,
lower panel) [5]. The BSSP4 expression level in meta-
static lung section foci of hyperthyroid was obviously
higher than euthyroid mice. Moreover, we observed T3-
induced cancer cell invasion and BSSP4 expression
in vivo, suggesting that T3 influences tumor motility via
BSSP4 regulation.
Discussion
In a previous stable isotope labeling with amino acids in
cell culture (SILAC)-based quantitative proteomics study
of a thyroid hormone-regulated secretome in human
hepatoma cells, BSSP4 was shown to be upregulated
3.25-fold by T3 [5]. Here we have shown that BSSP4 is
modulated by T3 at both the mRNA and protein levels.
Additional studies confirmed that T3 regulates BSSP4
at the transcriptional level, and TR and RXRα complexes
directly bind TRE between positions −609 and −594 of the
Figure 8 BSSP4 expression is upregulated in vitro and in vivo, and the T/N ratios of BSSP4 and TR levels are positively correlated in
HCC. (A) The BSSP4, TRα/TRβ and P-Erk proteins in HCC specimens were determined using Western blotting. TRs and BSSP4 were overexpressed
in 12 representative tumor tissues. The correlations of T/N ratios between BSSP4 and TR (B) and BSSP4 and VEGF (C) were analyzed using linear
regression analysis. BSSP4 regulation by T3 at different concentrations (0, 1 and 10 nM) and time-points (24 and 48 h) was examined in J7-TRα1
cells at (D) both mRNA (D, upper panel) and protein (D, lower panel) levels using Q-PCR (D, upper panel) and Western blotting (D, lower panel),
respectively. (E) Lung sections of SCID mice injected with J7-TRα1 cells treated with hyper-T3 (hyperthyroid) and administered normal drinking
water (euthyroid) were analyzed with IHC (upper panel) and H & E (lower panel) staining to examine BSSP4 expression (upper panel) and tumor
foci (lower panel).
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pressing BSSP4 showed higher migration and invasion
abilities, both in vitro and in vivo. Moreover, T3 appears to
regulate BSSP4 via the ERK1/2/C/EBPβ/VEGF cascade,
leading to cancer cell progression. The sequential eventsfollowing BSSP4 activation by T3 in hepatoma cells are
illustrated in Figure 9.
BSSP4 was initially identified as a member of the serine
protease family [7]. More recently, we identified several
T3-modulated proteases, such as matrix metalloproteinases
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calcium-dependent endopeptidases involved in proteolytic
processing [21,22]. These proteases participate in cellular
processes and intercellular communication during cancer
progression and development [10,23,24]. Based on these
findings, we hypothesized that the BSSP4 protease plays a
role in T3-influenced cancer cell progression.
In cancer cell progression, epithelial-mesenchymal
transition (EMT) is an important step leading to loss of
cell-cell adhesion ability. E-cadherin is a transmembrane
protein that participates in rearrangement of the cytoskel-
eton and cell-cell junctions [25]. E-cadherin overexpression
attenuates tumor cell migration and metastasis [11,26].
When tumor cells from the epithelium transit to the mes-
enchymal type, N-cadherin expression is increased, and
subsequently, cell conformation is altered. Consequently,
migration and invasion abilities are increased after cells
acquire N-cadherin expression [27]. Notably, expression
of N-cadherin is increased and that of E-cadherin is
decreased in BSSP4-overexpressing cells, compared with
controls. We propose that BSSP4 accelerates tumor cell
migration through the EMT or alterations in N-cadherin
and E-cadherin expression.
VEGF is widely distributed in almost all malignant
cancers, and considered an important tumor angiogen-
esis factor. The growth factor influences the vascular
permeability of vascular endothelial cells and endothelial
cell proliferation and migration in vitro, and generates
new blood vessels in vivo. To date, several drugs have
been effectively used to target VEGF with the aim of inhi-
biting tumor growth in a mouse model [28]. Chang et al.
[29] reported that VEGF induces angiogenesis by distrust-
ing the balance between proteases and protease inhibitors
and causing basement membrane degradation. Highly
expressed VEGF and increased microvessel density are
correlated with decreased survival, and poor prognosis
and progression in cancers [30,31]. Roudnicky et al. [32]
demonstrated that VEGF is highly expressed in plasma of
bladder cancer, compared with healthy controls, and pro-
motes tumor cell migration via elevated expression of
endothelial cell-specific molecule 1 (endocan). Yen et al.
[33] reported that HBx induces cell proliferation and
VEGF expression by upregulating the mTOR signaling
pathway via IKK in HCC. BSSP4 and T3 enhanced VEGFTable 1 The number of HCC patients stratified by
TR/BSSP4/VEGF RNA expression levels
Target expression TR BSSP4 VEGF
Low 6 18 7
Median 11 8 13
High 35 26 32
The expression levels (T/N) of TR, BSSP4 and VEGF were determined by
QRT-PCR in HCC mRNA level (52 cases).secretion in the medium in both BSSP4-overexpressing
and hepatoma cells in our experiments. Accordingly, we
speculate that BSSP4 modulates cell motility through
regulation of VEGF in the medium.
C/EBPβ is a transcription factor that regulates several
target genes implicated in various processes, including cel-
lular proliferation, migration, survival, metabolism and in-
flammation, and has diverse functions in several cancers
[34]. Previously, Sebastian et al. [35] proposed that Ras-
induced cell cycle arrest and tumor suppression occur via
the ERK1/2 and C/EBPβ signaling pathways. Therefore,
C/EBPβ may be effective as an activator of transcription
factors and signal transducers, and modulate various
target genes in response to hormone treatment [36].
Additionally, some groups have proposed that C/EBPβ
is an effective regulator of oncogene-induced inflamma-
tory secretome [37]. Consistent with earlier reports, we
showed that BSSP4 increases C/EBPβ expression and cell
motility through the ERK signaling pathway after U0126
treatment in both stable BSSP4-overexpressing and hepa-
toma cell lines.
Olazabal et al. [38] proposed that the pituitary hor-
mone, prolactin, induces liver regeneration via activation
of transcription factors involved in cell proliferation and
liver-specific differentiation and metabolism, such as
C/EBP and HNF families and the angiogenic and survival
factors, VEGF and HIF-1α, after partial hepatectomy. Fur-
thermore, Montano and co-workers reported that VEGF
acts as a transcriptional target of HEXIM1, a transcription
factor, tumor suppressor and cyclin-dependent kinase in-
hibitor, via regulation of C/EBP to influence cell invasion
and myocardial proliferation and survival [39]. These data
are consistent with our report that VEGF functions as an
effector of the C/EBP pathway to influence cellular motil-
ity and may thus be employed as a downstream target.
Recently, the group of Clarke showed that a novel stroke
therapy agent, perlecan domain V, promotes angiogenesis
in brain endothelial cells, by inducing expression and
secretion of VEGF via phosphorylation of the ERK1/2
pathway [16]. Shen et al. [40] showed that Notoginseno-
side Ft1 (Ft1) stimulates angiogenesis by increasing VEGF
expression and simultaneously activating the ERK signal-
ing pathway. Feng and colleagues also proposed that low-
power laser irradiation (LPL1) promotes VEGF expression
and vascular endothelial cell proliferation via the ERK/Sp1
pathway [41]. In view of the several lines of evidence,
including our results, we propose that VEGF may be a
downstream signal and regulator mediating cell motility
and angiogenesis.
Previously, Yasuda et al. [6] showed that BSSP4 is a
protease catalyzing the conversion of pro-uPA to mature
uPA, suggestive of a role in the fibrinolysis reaction. The
fibrinolysis system is critical in the development of the
tumor microenvironment and vascular diseases, such as
Figure 9 Schematic representation of the pathway of TH-mediated cell motility. Schematic representation of the pathway of TH-mediated
cell motility. Addition of T3 (10 nM) to HepG2-TR α cells activates BSSP4 expression via direct binding of TR proteins to TRE (−609 ~ −594) of the
BSSP4 promoter. P-ERK and C/EBPβ were upregulated in the nucleus, and VEGF was highly secreted in the medium of the BSSP4-overexpressed
and T3-treated hepatoma cells. EMT-related proteins, such as E-cadherin and N-cadherin, were also influenced by BSSP4. BSSP4 and T3 exerted
similar effects to promote cell motility via the EMT process and ERK-C/EBP β-VEGF cascade in hepatoma cells.
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[8]. Furthermore, we propose that the blood coagulation
system is mediated by T3, based on MetaCore™ software
analysis using the SILAC-based quantitative approach [5].
BSSP4 is abundantly found in endothelial cells, leading to
the speculation that the protein is preferentially expressed
in vascular cells [6]. The uPA system (uPA, tPA, uPAR,
PAI-1 and BSSP4) is significantly linked with tumor cell
metastasis, which is frequently associated with significant
mortality and poor prognosis [5,8]. The uPA/uPAR system
is highly expressed in almost all human cancers, and associ-
ated with short survival and high metastatic potency [8].
Additionally, pro-uPA has been identified as a substrate of
BSSP4, which induces enhanced migration ability of pro-
uPA-expressing smooth cells via basement membrane
degradation [6]. In our experiments, BSSP4 enhanced mi-
gration and invasion abilities in HCC cell lines, both
in vitro and in vivo, similar to that observed by other
groups. In conclusion, T3-regulated BSSP4 may play a role
in vascular endothelial cell motility through activation of
VEGF to promote cancer cell progression.Conclusion
Our findings collectively support a potential role of T3
in cancer cell progression through regulation of the
BSSP4 protease via the ERK 1/2-C/EBPβ-VEGF cascade.
BSSP4 was overexpressed in clinical hepatocellular car-
cinoma (HCC) patients, compared with normal subjects,
and positively associated with TRα1 and VEGF to a sig-
nificant extent. Importantly, a mild association between
BSSP4 expression and distant metastasis was observed.
BSSP4 may thus be effectively utilized as a novel marker
and anti-cancer therapeutic target in HCC.Materials and methods
Cell culture
Human hepatoma cells, HepG2, Huh7 and J7, were rou-
tinely cultured at 37°C in a humidified atmosphere of
95% air and 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). HepG2 and J7 cell lines were stably trans-
fected with TRα1 (HepG2-TRα1#1, HepG2-TRα1#2 and
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cell line employed was HepG2-neo [42,43]. Huh7-BSSP4
and J7-BSSP4 represent the Huh7 and J7 cell lines
expressing BSSP4, respectively. Serum was depleted of
T3 (Td), as described previously [44].Preparation of conditioned medium
HepG2-TRα1#1, HepG2-TRα1#2, HepG2-TRβ1, HepG2-
neo, J7-TRα1, Huh7-BSSP4 and J7-BSSP4 cells were grown
to confluence in 10 cm cell culture dishes. Cells contacting
dishes were washed twice with PBS, and subsequently incu-
bated in serum-free medium and either treated with T3 for
24 h or left untreated. At the end of the treatment period,
conditioned medium (CM) was collected and concentrated
using spin columns with a molecular mass cut-off of 3 kDa
(Amicon Ultra, Millipore, Billerica, MA).Immunoblot analysis
Total cell lysates and conditioned media were prepared,
and protein concentrations determined with the Bradford
assay kit (Pierce Biotechnology, Rockford, IL). Equivalent
amounts of proteins were fractionated on a 10% sodium
dodecyl sulfate (SDS)-polyacrylamide gel. Separated pro-
teins were transferred on to a nitrocellulose membrane
(pH 7.9, Amersham Biosciences Inc., Piscataway, NJ),
blocked with 5% non-fat powdered milk, incubated with
specific primary antibodies at 4°C overnight, and subse-
quently hybridized with the respective secondary antibody
(HRP-conjugated mouse/rabbit/goat anti-IgG) for 1 h at
room temperature. Finally, immune complexes were visu-
alized using the chemiluminescence method with an ECL
detection kit (Amersham) on Fuji X-ray film, as described
previously [45].Quantitative reverse transcription polymerase chain
reaction (Q-RT-PCR)
Total RNA was extracted from four T3-treated HepG2
isogenic cell lines using TRIzol reagent, as described
previously [46]. Subsequently, cDNA was synthesized via
RT-PCR with the Superscript II kit (Life Technologies,
Karlsruhe, Germany). Real-time Q-RT-PCR was per-
formed on a 15 μl reaction mixture containing 750 nM
forward and reverse primers, varying amounts of template
and 1 × SYBR Green reaction mix (Applied Biosystems,
Foster City, CA). SYBR Green fluorescence was determined
using the ABI PRISM 7500 detection system (Applied Bio-
systems). Primers were designed using Primer Express Soft-
ware (Applied Biosystems). Genes were normalized against
the ribosomal binding protein (RiboL35A) gene. The hu-
man BSSP4 oligonucleotides used in this study include the
forward primer, 5′-GGTCCCAGAAGGTGGGTGTT −3,
and reverse primer, 5′- ACGCACCAGGGCAATGTC -3′.Cloning and activities of BSSP4 promoter fragments
Fragments of the BSSP4 promoter (positions −2066 to −7)
were ligated into the pA3TK vector (Promega Corp.,
Madison, WI), based on the published sequence. Several
serial deletion and mutant constructs of the BSSP4 pro-
moter were amplified via PCR and cloned into pA3TK.
Promoter sequences were confirmed using automated
DNA sequencing. HepG2-TRα1 cells treated with 10 nM
T3 for 24 h were cotransfected with 0.6 μg DNA/well of
pA3TK vector containing the BSSP4 promoter sequence
and 0.3 μg of SVβ plasmid, a β-galactosidase expression
vector (Clontech, Palo Alto, CA), in 24-well plates using
TurboFect in vitro transfection reagent (Fermentas, Glen
Burnie, MD) to determine the transcriptional activities of
TREs within the BSSP4 promoter. At the end of the treat-
ment period, transfected and non-transfected cells were
lysed, and luciferase and β-galactosidase activities mea-
sured. Luciferase activity was normalized to that of β-
galactosidase, as described earlier [47].Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed to examine the interactions
between TR and TRE on the BSSP4 promoter [45].
HepG2-TRα1 cells treated with 10 nM T3 for 24 h or left
untreated were harvested and cross-linked with 1% for-
maldehyde for 10 min at room temperature in DMEM
medium. Reactions were terminated by adding 0.125 M
glycine. Subsequently, cell lysates were washed three
times with PBS, and resuspended in lysis buffer (150 mM
NaCl, 5 mM EDTA, 50 mM Tris (pH 8.0), 0.1% SDS and
0.1% sodium deoxycholate) containing three protease
inhibitors (1 mM PMSF, aprotinin, and leupeptin). Cell
lysates were sonicated with a Misonix Sonicator 3000
Homogenizer (Mandel Scientific Company Inc., Guelph,
ON, Canada) to disrupt chromatin. Sonicated DNA was
between 200 and 1000 bp in length. Products were pre-
cleared with 60 μl protein A/G agarose (Sigma Chemicals,
St. Louis, MO) for 2 h at 4°C. Complexes were immuno-
precipitated with anti-TR (kindly provided by the labora-
tory of Dr. S-Y Cheng at the National Cancer Institute),
anti-RXRα (Santa Cruz Biotechnology, Santa Cruz, CA)
and anti-IgG antibodies (R & D Systems, Inc., Minneap-
olis, MN). The 100 bp fragment of the BSSP4 promoter
containing the predicted TRE region was amplified via
PCR with the forward primer, 5′- CTCCAGGAACGACA
GGAGGGCG - 3′, and reverse primer, 5′-GCCTGGGT
TTGGAGAGGCTGAAGTC- 3′.Proliferation assay
Cells (4 × 104) were seeded on a 6 cm dish and harvested
at 1–7 days. The total number of cells in each condition
provided a cell growth index via cell counting. Values
are presented as fold increase in Huh7-BSSP4 and J7-
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were analyzed using one-way ANOVA.
Cloning of BSSP4
Total RNA (1 μg) was reverse-transcribed using Superscript
II reverse transcriptase (Invitrogen) and Oligo (dT) to
synthesize template cDNA. BSSP4 cDNA was amplified
via PCR with the forward primer, 5S - CCAAGCTTA
TGGTGGTTTCTGGAGCGCCC-3′, and reverse primer,
5′ - CCGGAATTCCTAGGAGCGCGCGGCGG −3′, for
30 cycles at 95°C for 1 min, 60°C for 1 min and 72°C for
2 min. The BSSP4 open reading frame was ligated into
pcDNA 3.0 expression vector, and the resulting construct
sequenced to confirm the presence of the gene.
Establishing Huh7 and J7 cell lines stably overexpressing
BSSP4
The Huh7 cell line was transfected with the BSSP4
cDNA construct in 10 cm cell culture dishes using Lipo-
fectamine Reagent (Invitrogen). After 24 h, transfected
cells were transferred to medium containing G418
(400 μg/ml) for selection until the generation of a single
cell clone. Expression of BSSP4 in Huh7 and J7 cells was
detected using Western blotting.
Effect of knocked-down BSSP4 expression
Short hairpin RNA clones targeting BSSP4 were purchased
from the National RNAi Core Facility (Institute of Mo-
lecular Biology, Academia Sinica, Taiwan). Transfection of
shRNA to against the endogenous BSSP4 gene in Mahlavu
and J7-TR cells was transit performed using the Turbofect
reagent (Invitrogen). The repression of the BSSP4 was
confirmed by western blot analysis.
In vitro migration and invasion assays
The influence of BSSP4 on migration and invasion abilities
of Huh7-BSSP4 and J7-BSSP4 cells was determined with a
rapid in vitro assay (Transwell) (Falcon BD, Franklin Lakes,
New Jersey), as described previously [48]. Briefly, cell
density was adjusted to 105 cells/ml, and 100 μl of the sus-
pension seeded on either non-matrigel-coated (migration)
or matrigel-coated (invasion) (Becton-Dickinson) upper
chambers of the Transwell plate. For both assays, the pore
size of the upper chamber was 8 mm. The medium in the
upper chamber was serum-free DMEM, while the lower
chamber contained DMEM supplemented with 20% fetal
bovine serum (FBS). After incubation for 24 h at 37°C,
cells traversing the filter from the upper to lower chamber
were examined via crystal violet staining and cell counting.
Experiments were performed at least three times.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues from the
lung of SCID mice were evaluated by hematoxylin andeosin (H & E) staining and immunohistochemistry using
polyclonal antibody against BSSP4 (GeneTex, Inc, San
Antonio, Texas) after the avidin-biotin complex method,
as described previously. The positive staining consisted of
cancer cells with dark brown of BSSP4 immunoreactivity.
Animals
Similar conditions were employed with SCID mice con-
taining various T3 levels (Group A to B) induced via in-
jection of J7-TR cells [5]. Mice were divided into two
groups, specifically, Group A (euthyroid) comprising
control mice given normal drinking water, and Group B
(hyperthyroid) administered drinking water augmented
with T3 (2 mg/L) (Sigma Chem. Co., St. Louis, MO) after
inoculation of tumor cells. Mice were sacrificed after
about 1 month injection, livers and lungs were removed
for tumor biopsy, and the T3 and TSH levels determined.
The T3 and TSH levels in the serum of group A were
45.5 ng/dl and 0.246 mIU/ml, and in group B were
619 ng/dl and 0.008 mIU/ml, respectively. Tumor volume
was calculated using the following equation: length ×
height × width. Formalin-fixed and paraffin-embedded tis-
sues from SCID mice were evaluated by hematoxylin and
eosin (H & E) staining and immunohistochemistry using
polyclonal antibody against BSSP4 (GeneTex). All proce-
dures were performed under sterile conditions in a lam-
inar flow hood. Animal experiments were performed in
accordance with United States National Institutes of
Health guidelines and Chang-Gung Institutional Animal
Care and Use Committee Guide for the Care and Use of
Laboratory Animals.
Human HCC specimens
With informed consent, patients with HCC diagnosed
between 2000 and 2003 were selected consecutively for
this study. All samples of HCC tissues with paired adja-
cent normal liver tissues were obtained during surgical re-
section from the Chang Gung Memorial Hospital medical
research center for western blot and Q-RT-PCR analysis.
The study protocol was approved by the Medical Ethics
and Human Clinical Trial Committee at Chang-Gung
Memorial Hospital.
Statistical analysis
Data are expressed as mean values ± SEM of at least three
experiments. Statistical analysis was performed using the
Student’s t test and one-way ANOVA analysis. P < 0.05
was considered statistically significant.
Additional files
Additional file 1: Figure S1. Effect of TR on T3 induction of BSSP4
expression in SK-Hep-1 cell. The TRα and TRβ expression were depleted
with siRNA in SK-Hep1 cell (A). The BSSP4 protein level was examined in
Chen et al. Molecular Cancer 2014, 13:162 Page 16 of 17
http://www.molecular-cancer.com/content/13/1/162the conditioned medium of SK-Hep-1 and SK-Hep-1-siTRαβ cells treated
with 1 or 10nM T3 (24 h and 48 h) and analyzing by Western blotting (B).
Additional file 2: Figure S2. Expression of BSSP4 in hepatoma cell
lines. The BSSP4, or TRα/TRβ expression levels were detected in six
available hepatoma cells (SK-Hep-1, Mahlavu, Huh7, HepG2, J7 and Hep-
3B) analyzing by Western blotting.
Additional file 3: Figure S3. Effect of proliferation ability by BSSP4 in
hepatoma cell lines. Cell growth rates were determined from 1 to 7 days,
and expressed as the total number of cells representing index of
proliferation ability. (A) Huh7, (B) J7.
Additional file 4: Figure S4. Regulation of VEGFR by BSSP4 and T3 in
hepatoma cells. The p-VEGFR and VEGFR expression were examined in
Huh7 BSSP4-overexpressing (A) and T3-treated HepG2-TRα1 (B) Cells by
Western blotting.
Additional file 5: Figure S5. Pathways or molecules regulated by
BSSP4 in hepatoma cells. Several categories based on the functions such
as (A) cytokines and chemokine pathway (IL-18, CCL7, CXCL12), (B) cell to
cell adhesion pathway (PNN, SYK, MCAM), (C) metastasis-related genes
(GNRH1, TIMP2, KISS1R, TSHR, TRPM1, SSTR2) (D) Transcription factors and
regulators (RORB, NR4A3, SMAD2, SMAD4) (E) ECM cleavage pathway
(MMP7) and (F) cell cycle regulation (PTEN) were determined by
metastasis-associated PCR array in Huh7 BSSP4-overexpressing stable cells.
Additional file 6: Figure S6. Clinicopathological correlation of BSSP4
expression and several parameters in hepatoma patients.
Additional file 7: Figure S7. Positive correlation of BSSP4 and TRα/TRβ
expression levels. The correlation between BSSP4 and TRα (A) and TRβ (B)
were analyzed from Oncomine microarray data sets [1].
Additional file 8: Figure S8. Clinicopathological correlation of BSSP4
expression and overall survival rate in hepatoma patients.
Abbreviation
BSSP4: Brain-specific serine protease 4; C/EBPβ: CCAAT/enhancer-binding
protein β; ERK: Extracellular signal-regulated kinase; HCC: Hepatocellular
carcinoma; MAPK: Mitogen-activated protein kinase; TH: Thyroid hormone;
TREs: Thyroid hormone response elements; uPA: urokinase-type plasminogen
activator; VEGF: Vascular endothelial growth factor.
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